Upon completion of this course, you will be able to:
MODULE 01
Foundations of BCMA-Targeted Therapy for Multiple Myeloma:
1. Recognize the epidemiological trends and diagnostic criteria of multiple myeloma.
2. Identify and describe the six main therapeutic options for multiple myeloma.
3. Discuss an overview of BCMA-targeted immunotherapies for multiple myeloma, such as
chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies (BsAbs), and antibody-drug
conjugates (ADCs), including their mechanisms of action.
4. Compare the advantages and disadvantages of the immunotherapy options for treating multiple
myeloma.
MODULE 02
Toxicity Management and Interprofessional Collaboration in BCMA-Targeted Immunotherapy
1. Identify the information needs of patients with multiple myeloma.
2. Identify the interprofessional care team with a focus on the role of the oncology nurse in
providing BCMA-specific patient education.
3. Recognize and describe the various adverse events that may occur following treatment for
multiple myeloma—including Cytokine Release Syndrome (CRS), Immune Effector Cell-
Associated Neurotoxicity Syndrome (ICANS), ocular toxicity, and infections—focusing on their
pathology, assessment, and management strategies.
Dr. Bethany Monteith, Division of Hematology, Queen’s University
Dr. Janique Dyba, Division of Hematology, Queen’s University
Dr. Julie Stakiw, Medical Director, Oncology & Clinical Professor Hematological Oncology, University of Saskatchewan
Dr. Jacob Rullo, Department of Ophthalmology
Dr. Sarah Ryan, Division of Hematology, Queen’s University
Nurse Practitioner Leah Jodoin, Department of Oncology, Kingston Health Sciences Centre
Mme. Claudia Trost, Patient Partner, Subject Matter Expert, Support Group Leader, Kingston Myeloma Group
Nurse Tracey Froess, Kingston Health Sciences Centre
